成人脑肿瘤患者与功能结局相关的身体功能测量:范围综述

IF 2.5 Q2 CLINICAL NEUROLOGY
Neuro-oncology practice Pub Date : 2025-03-26 eCollection Date: 2025-08-01 DOI:10.1093/nop/npaf036
Tara S Davis, Emory Hsieh, Bennett A McIver, Kaitlynn Slattery, McKenzie C Kauss, Diane Cooper, Vivian A Guedes, Terri S Armstrong, Michelle L Wright
{"title":"成人脑肿瘤患者与功能结局相关的身体功能测量:范围综述","authors":"Tara S Davis, Emory Hsieh, Bennett A McIver, Kaitlynn Slattery, McKenzie C Kauss, Diane Cooper, Vivian A Guedes, Terri S Armstrong, Michelle L Wright","doi":"10.1093/nop/npaf036","DOIUrl":null,"url":null,"abstract":"<p><p>Neuro-oncology researchers and clinicians rely mostly on subjective measures to evaluate physical functioning (PF) and predict survival in primary brain tumor (PBT) patients. Exploring alternative clinical outcome assessment (COA) measures may identify more objective measures that better quantify PF in PBT patients. A scoping review was conducted to identify studies related to PF measures used in PBT patients. Using the PRISMA-SCRA guideline 3 databases (PubMed, Web of Science, and Cochrane Library) were searched on January 25, 2024. Reviewers performed an independent review of titles, abstracts, and full text using covidence systematic review software and a standardized Microsoft Excel form for extracting data. 1093 publications were identified; 49 studies met eligibility criteria. Studies used a variety of PF measures evaluated at different time points, ranging from preintervention to 3 years or more postintervention. 39 PF COA measures were identified. Of the 39, 3 clinician-reported measures (ClinRO) [KPS, ECOG, and FIM] are validated for PBT. Many measures found are standardized for other neurological diseases including performance (PerfO) and patient-reported outcome (PRO) measures. Validation of additional COA types (PerfO and PRO) that are complementary to the ClinRO measures already validated for the PBT population should be established. Measures of interest should include the evaluation of walking due to its clinical relevance and indication for overall PF.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 4","pages":"571-584"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349772/pdf/","citationCount":"0","resultStr":"{\"title\":\"Measures of physical functioning in adults with brain tumor associated with functional outcomes: A scoping review.\",\"authors\":\"Tara S Davis, Emory Hsieh, Bennett A McIver, Kaitlynn Slattery, McKenzie C Kauss, Diane Cooper, Vivian A Guedes, Terri S Armstrong, Michelle L Wright\",\"doi\":\"10.1093/nop/npaf036\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Neuro-oncology researchers and clinicians rely mostly on subjective measures to evaluate physical functioning (PF) and predict survival in primary brain tumor (PBT) patients. Exploring alternative clinical outcome assessment (COA) measures may identify more objective measures that better quantify PF in PBT patients. A scoping review was conducted to identify studies related to PF measures used in PBT patients. Using the PRISMA-SCRA guideline 3 databases (PubMed, Web of Science, and Cochrane Library) were searched on January 25, 2024. Reviewers performed an independent review of titles, abstracts, and full text using covidence systematic review software and a standardized Microsoft Excel form for extracting data. 1093 publications were identified; 49 studies met eligibility criteria. Studies used a variety of PF measures evaluated at different time points, ranging from preintervention to 3 years or more postintervention. 39 PF COA measures were identified. Of the 39, 3 clinician-reported measures (ClinRO) [KPS, ECOG, and FIM] are validated for PBT. Many measures found are standardized for other neurological diseases including performance (PerfO) and patient-reported outcome (PRO) measures. Validation of additional COA types (PerfO and PRO) that are complementary to the ClinRO measures already validated for the PBT population should be established. Measures of interest should include the evaluation of walking due to its clinical relevance and indication for overall PF.</p>\",\"PeriodicalId\":19234,\"journal\":{\"name\":\"Neuro-oncology practice\",\"volume\":\"12 4\",\"pages\":\"571-584\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349772/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/nop/npaf036\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npaf036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

神经肿瘤学研究人员和临床医生主要依靠主观测量来评估原发性脑肿瘤(PBT)患者的身体功能(PF)和预测生存。探索替代临床结果评估(COA)措施可以确定更客观的措施,更好地量化PBT患者的PF。进行了一项范围审查,以确定与PBT患者中使用的PF测量相关的研究。使用PRISMA-SCRA指南3数据库(PubMed, Web of Science和Cochrane Library)于2024年1月25日检索。审稿人使用covid - 19系统审查软件和用于提取数据的标准化Microsoft Excel表格对标题、摘要和全文进行独立审查。确定了1093种出版物;49项研究符合资格标准。研究使用了不同时间点的各种PF测量方法,从干预前到干预后3年或更长时间。确定了39个PF COA措施。在39项临床报告的测量中,有3项(ClinRO) [KPS、ECOG和FIM]对PBT进行了验证。发现的许多测量方法对于其他神经系统疾病是标准化的,包括性能(PerfO)和患者报告的结果(PRO)测量。应该建立额外的COA类型(PerfO和PRO)的验证,以补充已经为PBT人群验证的ClinRO措施。由于其临床相关性和对整体PF的适应症,感兴趣的措施应包括步行的评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Measures of physical functioning in adults with brain tumor associated with functional outcomes: A scoping review.

Neuro-oncology researchers and clinicians rely mostly on subjective measures to evaluate physical functioning (PF) and predict survival in primary brain tumor (PBT) patients. Exploring alternative clinical outcome assessment (COA) measures may identify more objective measures that better quantify PF in PBT patients. A scoping review was conducted to identify studies related to PF measures used in PBT patients. Using the PRISMA-SCRA guideline 3 databases (PubMed, Web of Science, and Cochrane Library) were searched on January 25, 2024. Reviewers performed an independent review of titles, abstracts, and full text using covidence systematic review software and a standardized Microsoft Excel form for extracting data. 1093 publications were identified; 49 studies met eligibility criteria. Studies used a variety of PF measures evaluated at different time points, ranging from preintervention to 3 years or more postintervention. 39 PF COA measures were identified. Of the 39, 3 clinician-reported measures (ClinRO) [KPS, ECOG, and FIM] are validated for PBT. Many measures found are standardized for other neurological diseases including performance (PerfO) and patient-reported outcome (PRO) measures. Validation of additional COA types (PerfO and PRO) that are complementary to the ClinRO measures already validated for the PBT population should be established. Measures of interest should include the evaluation of walking due to its clinical relevance and indication for overall PF.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neuro-oncology practice
Neuro-oncology practice CLINICAL NEUROLOGY-
CiteScore
5.30
自引率
11.10%
发文量
92
期刊介绍: Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信